Emerging DPP-4 inhibitors: focus on linagliptin for type 2 diabetes
Baptist GallwitzDepartment of Medicine IV, Eberhard-Karls-University Tübingen, Tübingen, GermanyAbstract: The first dipeptidyl-peptidase-IV (DPP-4) inhibitor for the treatment of type 2 diabetes became available in 2006. Since then, the number of DPP-4 inhibitors has increa...
Guardado en:
Autor principal: | Gallwitz B |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2013
|
Materias: | |
Acceso en línea: | https://doaj.org/article/cd1f495ee6a240d9bfe076e1ace56906 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin
por: Bo Ahrén
Publicado: (2010) -
Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes
por: Kishimoto M
Publicado: (2013) -
Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin
por: Ahren B
Publicado: (2010) -
Managing diabetic patients with moderate or severe renal impairment using DPP-4 inhibitors: focus on vildagliptin
por: Russo E, et al.
Publicado: (2013) -
Potential role of linagliptin as an oral once-daily treatment for patients with type 2 diabetes
por: Hoimark L, et al.
Publicado: (2012)